The gene and protein expression data support the responsiveness of patient-derived HCC CAFs to the LXRα agonist T0901317, and an antagonistic effect of LXRα signaling against TGFβ-mediated myofibroblast gene expression in certain HCC CAFs. This evidence concerns the gene NR1H3 and hepatocellular carcinoma.